| 产品详情 |
| Edit |   |
|---|
| Product Name | Troglitazone |
|---|
| Description | Purity >98%. Troglitazone is a TZD which was approved for the treatment of insulin resistance and hyperglycemia in Type II diabetes, under the trade name Resulin(tm), but was withdrawn from the market due to hepatotoxicity. Troglitazone is a potent and selective PPARGamma agonist. The EC50 values for transactivation of human and mouse PPARGamma in a cell-based assay are 0.55 and 0.78 uM, respectively. In the same assay system, no activation of PPARAlpha and PPARDelta was observed at concentrations up to 10 uM. Troglitazone binds to the PPARGamma ligand-binding domain (LBD) but fails to induce interaction of the PPARGamma LBD with the transcriptional coactivators SRC-1, TIF2, AIB1, p300, or TRAP220. Troglitazone also induces cell cycle arrest and apoptosis in several cancer cell lines with an EC50 of 10 uM. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazlidinedione, Resulin™ |
|---|
| Gene, Accession, CAS # | CAS: 97322-87-7 |
|---|
| Catalog # | LS-H10322 |
|---|
| Price | |
|---|
| Order / More Info | Troglitazone from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|